ADTRALZA 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA

USDailyMed:Tralokinumab D11AH07(WHO) CA:℞-only/Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyRx-only 1044515-88-9N DB12169Y none GK1LYB375A D09979 Tralokinumabsold under the brand namesAdtralza(EU/UK) andAdbry(US) among others, is ahuman monoclonal antibodyused f‍‍‍‍‍‍​​​‍​​​​​​or the treatment ofatopic dermatitis.Tralokinumab targets the cytokineinterleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021.It was approved for medical use in the United States in December 2021.The U.S.Food and Drug Administration(FDA) considers it to be afirst-in-class medication.